Fluticasone/salmeterol treatment for chronic obstructive pulmonary disease (COPD) may be associated with a higher risk of active tuberculosis (TB), according to a study published in BMC Infectious Diseases.

In most settings, children and adults are at equal risk of developing multidrug resistant (MDR) or rifampicin resistant (RR) tuberculosis (TB), but there are important gaps in data that limit this understanding, according to a study that was recently published in the European Respiratory Journal.

Darunavir/ritonavir administered with rifampicin causes hepatotoxicities in people living with HIV, according to results of a study published in the Journal of Antimicrobial Chemotherapy.

In patients without a contraindication, rifampicin may be the safest treatment option for latent tuberculosis (TB) infection, according to results of a study published in the Lancet Infectious Diseases.

As a result of low drug resistance in pleural tuberculosis (TB), treatment regimens of pleural TB may include fewer drugs and maintain appropriate levels of efficaciousness, according to a study published in the European Journal of Clinical Microbiology & Infectious Diseases.

Dolutegravir in combination with 2 non-nucleot(s)ide reverse transcriptase inhibitors (NRTIs) is well tolerated and may produce rapid virologic and immunologic responses in patients with tuberculosis (TB) and HIV who have not previously received treatment , according to a study published in Clinical Infectious Diseases.